Sientra to Launch State-of-the-Art Innovation Facility

Sientra Lab and Innovation Center of Excellence (SLICE) reinforces dedication to drive value as a diversified global aesthetics company

SANTA BARBARA, Calif., July 31, 2018 /PRNewswire/ -- Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, today announced its investment in opening a new state-of-the-art Sientra Lab and Innovation Center of Excellence (SLICE) near its corporate headquarters in Santa Barbara, CA. SLICE is expected to open in August 2018, with a focus on driving development, research and innovation of surgical products, services and solutions within its Breast Products business segment.

The new development lab facility will enable Sientra to accelerate its efforts on key portfolio additions and enhancements. It will also better enable the company to leverage its exceptional products, people and surgeon relationships.

"SLICE represents Sientra's steadfast commitment to investing in the advancement of new solutions for board-certified surgeons and their patients," said Jeffrey M. Nugent, Chairman and Chief Executive Officer of Sientra. "At a time when many of our peers are decreasing their investments, our new facility will allow Sientra to continue to grow and diversify our portfolio, while strengthening the safety, reliability and quality of our products. SLICE will be led by Sientra's Vice President of Innovation and Product Development, Dan Carlisle, a 30-year industry veteran named as inventor or co-inventor on numerous patents in the aesthetic plastic surgery field. He will be responsible for designing, refining and improving new products for the global aesthetic market."

SLICE will act as a formal collaboration initiative to more regularly bring together Sientra's experienced Research and Development and Clinical teams with Sientra's medical advisory board, board-certified surgeons, technical experts and consultants. This group of trusted experts will help advance solutions and bring meaningful improvements on key clinical practices to board-certified surgeons.

"SLICE is another example of how Sientra continues to uphold its commitment to improving the plastic surgery community," said Bruce Van Natta, MD, Indianapolis, IN. "By giving us more opportunities to work directly with experts and other board-certified plastic surgeons, we can shape and contribute to the development of new products and technology – all of which will ultimately help us achieve the very best outcomes for our patients."

About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients' lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its OPUS™ breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products including BIOCORNEUM®, the professional choice in scar management, and miraDry®, the only FDA cleared device to reduce underarm sweat, odor and permanently reduce hair of all colors.

Media Contact:
Rosalyn d'Incelli
(805) 452-5421

Cision View original content:

SOURCE Sientra

Nasdaq: SIEN

Stock Quote: NASD

$0.84 -0.04
Volume 452,889
Previous Close 0.88
Intraday High 0.89
Intraday Low 0.81
Pricing delayed 20 minutes
Price Change % Change -4.95% 52 Week High 9.14 52 Week Low 0.80 Today's Open 0.89 Jun 29, 2022 04:00 PM

Investor Contact

Sientra Investor Relations